Skip to content

The AMD Experts

50196296_795957517416981_458178117475762176_n

Our Team

The MacuLogix team is committed to empowering primary eye care professionals with the technology and tools needed to create AMD Centers of Excellence®.

Bill McPhee, the President and CEO of MacuLogix, shares his personal story of why he joined the company and adopted its vision of eliminating blindness caused by AMD.

The AdaptDx is especially useful for optometrists and general ophthalmologists who see many patients with “normal” clinical exams, since it can detect subclinical AMD up to three years before clinical onset. With the AdaptDx, you will be in the front line in detecting these patients and will be able to carefully monitor and treat those with subclinical AMD.

Dr. Shawn Lewis1 Shawn Lewis, MD View all testimonials

Latest News & Upcoming Events

View More
Article: October 1, 2019 | Optometric Management

Use Functional and Structural Testing For Early Diagnosis

Dr. Leo Semes, OD, FAAO presents two cases that illustrate the importance of functional and structural testing in subclinical AMD detection, so eye care doctors can increase the likelihood of an excellent patient experience.

Article: September 17, 2019 | Women in Optometry

Ability to Quantify AMD Changes Is a Game-Changer

The AdaptDx is changing the way Dr. Donna Shotwell and many other eye care professionals manage their AMD patients.

Blog: September 10, 2019

Do You Know Your ABCs…of AMD (Age-Related Macular Degeneration)?

Our Senior VP of Global Sales, Armond Dantino narrates his grandmother’s battle with AMD. He drives home the point that patients need to recognize early signs of AMD and be proactive in order to mitigate the consequences of this progressive eye disease.

Put Our Expertise to Work

Testing with AdaptDx

AdaptDx identifies impaired dark adaptation—the earliest warning sign of AMD.

Guiding AdaptDx Implementation

Each AdaptDx purchase is supported by our AMD Excellence Program™ to help you achieve your patient care and practice revenue goals.